Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Large Decline in Short Interest

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest totaling 40,790 shares, a decrease of 25.7% from the February 26th total of 54,874 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average daily volume of 51,489 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Chemomab Therapeutics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Chemomab Therapeutics has a consensus rating of “Hold” and an average target price of $25.00.

Chemomab Therapeutics Trading Up 1.4%

CMMB stock opened at $1.48 on Tuesday. The business’s 50-day moving average price is $1.69 and its two-hundred day moving average price is $2.23. The firm has a market cap of $10.64 million, a PE ratio of -0.58 and a beta of 0.40. Chemomab Therapeutics has a 1-year low of $1.35 and a 1-year high of $5.88.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). On average, analysts forecast that Chemomab Therapeutics will post -1 earnings per share for the current year.

Institutional Trading of Chemomab Therapeutics

Several hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in Chemomab Therapeutics in the fourth quarter valued at approximately $31,000. Kestra Private Wealth Services LLC bought a new stake in shares of Chemomab Therapeutics during the fourth quarter worth $85,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Chemomab Therapeutics during the fourth quarter worth $132,000. 46.05% of the stock is currently owned by institutional investors and hedge funds.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.